SAB BIO held cash and equivalents of $12.9 million as of March 31, 2025, compared to $20.8 million as of December 31, 2024. Samuel Reich, Chairman and CEO of SAB BIO, stated, “We have made strong progress this quarter on our corporate strategy and mission to deliver a transformational therapy that can halt or delay the progression of type 1 diabetes. Based on our recent positive Phase 1 topline data for SAB-142, we have seen accelerating momentum across the T1D landscape regarding the therapeutic potential of SAB-142.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SABS:
- SAB Biotherapeutics Reports 2024 Financial Results and Advances T1D Therapy
- SAB Biotherapeutics price target lowered to $20 from $25 at Chardan
- Promising Outlook for SAB Biotherapeutics’ SAB-142: Positive Phase 1 Results and Future Growth Potential Justify Buy Rating
- SAB Biotherapeutics held cash and equivalents of $20.8 million at end of 2024